Display options
Cite
Franko J, Le VH, Tee MC, et al. Signet ring cell carcinoma of the gastrointestinal tract: National trends on treatment effects and prognostic outcomes. Cancer Treat Res Commun. 2021;29:100475doi: 10.1016/j.ctarc.2021.100475.
Franko, J., Le, V. H., Tee, M. C., Lin, M., Sedinkin, J., Raman, S., & Frankova, D. (2021). Signet ring cell carcinoma of the gastrointestinal tract: National trends on treatment effects and prognostic outcomes. Cancer treatment and research communications, 29100475. https://doi.org/10.1016/j.ctarc.2021.100475
Franko, Jan, et al. "Signet ring cell carcinoma of the gastrointestinal tract: National trends on treatment effects and prognostic outcomes." Cancer treatment and research communications vol. 29 (2021): 100475. doi: https://doi.org/10.1016/j.ctarc.2021.100475
Franko J, Le VH, Tee MC, Lin M, Sedinkin J, Raman S, Frankova D. Signet ring cell carcinoma of the gastrointestinal tract: National trends on treatment effects and prognostic outcomes. Cancer Treat Res Commun. 2021;29:100475. doi: 10.1016/j.ctarc.2021.100475. Epub 2021 Oct 11. PMID: 34655861.
Copy Download .nbib Format: NLM
Share it on

Cancer Treat Res Commun. 2021;29:100475. doi: 10.1016/j.ctarc.2021.100475. Epub 2021 Oct 11.

Signet ring cell carcinoma of the gastrointestinal tract: National trends on treatment effects and prognostic outcomes.

Cancer treatment and research communications

Jan Franko, Viet H Le, May C Tee, Mayin Lin, Jessica Sedinkin, Shankar Raman, Daniela Frankova

Affiliations

  1. MercyOne Medical Center, Des Moines, IA, USA. Electronic address: [email protected].
  2. MercyOne Medical Center, Des Moines, IA, USA.
  3. MercyOne Medical Center, Des Moines, IA, USA; Des Moines University, Des Moines, IA, USA.

PMID: 34655861 DOI: 10.1016/j.ctarc.2021.100475

Abstract

BACKGROUND: Signet ring cell carcinoma (SRCC) is a distinct malignancy occurring across the tubular gastrointestinal tract (tGIT). We comprehensively examined the outcomes of patients diagnosed with SRCC across tGIT.

METHODS: SRCC and not-otherwise-specified adenocarcinoma (NOS) patients reported to the National Cancer Database from 2004 to 2015 were included. Baseline characteristics, outcomes and site-specific adjusted hazard ratios (aHR) derived from Cox models of SRCC patients were compared to those of NOS patients. Overall survival (OS) was primary endpoint.

RESULTS: A total of 41,686 SRCC (4.6%) and 871,373 NOS patients (95.4%) were included. SRCC patients were younger (63.1 ± 14.7 vs. 67.0 ± 13.4 y, p < 0.001) and more likely to present with Stage IV disease than NOS patients (42.5% vs. 24.5%, p < 0.001). Stomach (n = 24,433) and colon (n = 9,914) contributed highest frequency of SRCC. SRCC histology was associated with shorter OS (aHR = 1.377, p < 0.001) in multivariate model. There was an interaction between SRCC and chemotherapy effects on risk of death (interaction aHR = 1.072, p

CONCLUSION: Significant negative prognostic effect associated with SRCC is site-dependent across the GIT. Surgical and or systemic therapy was associated with improved OS among SRCC patients, but remained lower than NOS patients. Further understanding of gastrointestinal SRCC molecular profile is needed to better inform future treatment strategies.

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Keywords: Colon carcinoma; Esophagus carcinoma; Gastric carcinoma; Rectal carcinoma; Small bowel carcinoma

Publication Types